Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Coppus, Antonia M.W.a; b; * | Evenhuis, Heleen M.c | Verberne, Gert-Janb | Visser, Frank E.d | Eikelenboom, Piete | van Gool, Willem A.e | Janssens, A. Cecile J.W.a | van Duijn, Cornelia M.a
Affiliations: [a] Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands | [b] Dichterbij, Centre for the Intellectually Disabled, Gennep, The Netherlands | [c] Department of General Practice, Intellectual Disability Medicine, Erasmus MC, Rotterdam, The Netherlands | [d] s'-Heeren Loo-Midden Nederland, Centre for the Intellectually Disabled, Ermelo, The Netherlands | [e] Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
Correspondence: [*] Corresponding author: Dr. AMW Coppus, Department of Epidemiology & Biostatistics, P.O Box 2040, 3000 CA Rotterdam, The Netherlands. Tel.: +311 07043394; Fax: +311 07044657; E-mail: [email protected].
Abstract: In a prospective longitudinal cohort study of dementia and mortality in persons with Down syndrome aged 45 years and older, 85 postmenopausal women were followed for a mean follow-up time of 4.3 years (range 0.0 to 7.4 years). The effect of age at menopause on age at diagnosis of dementia and survival was estimated using correlation analysis and Cox Proportional Hazard Model. We found a significant correlation between age at menopause and age at diagnosis of dementia (ρ = 0.52; p < 0.001), and between age at menopause and age at death (ρ = 0.49; p = 0.01). Early age at menopause is associated with a 1.8 fold increased risk of dementia: Hazard Ratio (HR): 1.82 (95%Confidence Interval (CI): 1.31–2.52) and with risk of death: HR: 2.05 (95%CI: 1.33–3.16). Our study suggests that age at menopause in women with Down syndrome is a determinant of age at onset of dementia and mortality.
Keywords: Alzheimer's disease, APOE genotype, Down syndrome, menopause, mortality
DOI: 10.3233/JAD-2010-1247
Journal: Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 545-550, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]